# Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

> **NCT00486265** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 47 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** AZD4877

## Key facts

- **NCT ID:** NCT00486265
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** 2009-07
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow response following a maximum of 2 induction courses of therapy
- **Last updated:** 2010-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486265, "Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00486265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*